At any one time the University of Oxford sponsors around 1,000 academic designed and led clinical research studies within the EU of which about 150 are interventional trials ranging from phase I to phase IV. The University sponsors approximately 350 further studies outside the EU, largely through its Centre for Tropical Medicine and Global Health.
Often in partnership with Oxford University Hospitals Foundation NHS Trust or Oxford Health Foundation NHS Trust most of the EU-based studies are run by one of the University’s six UKCRC fully registered specialist clinical trials units:
- Clinical Trial Service Unit and Epidemiological Studies Unit specializing in major large scale studies and trials of chronic disease;
- Diabetes Trials Unit national and multinational trials of the management and treatment of diabetes;
Oxford Clinical Trials Research Unit which integrates the following trials groups
- Centre for Statistics in Medicine
- Critical Care, Trauma and Rehabilitation Trials Group
- Gastroenterology Trials Group
- Oncology Clinical Trials Office (all phases)
- Respiratory Trials Unit
- Surgical Intervention Trials Unit
- NPEU Clinical Trials Unit conducts multicentre trials of a broad range of interventions for women and their families during pregnancy, childbirth, the newborn period and early childhood;
- Oxford Cognitive Health and Neuroscience Clinical Trials Unit which undertakes trials of therapies for neurological conditions, mental illness and cognitive impairments;
- Primary Care and Vaccines Collaborative Clinical Trials Unit which integrates the Primary Care Trials Unit and the Oxford Vaccine Group
c. 1,000 academic designed and led clinical research studies within the EU
Approximately 350 further studies outside the EU
Clinical Trials News
11 November 2019
Nuffield Department of Clinical Neuroscience’s Associate Professor Andrea Nemeth is leading the Oxford part of a gene therapy trial for Hungtinton’s disease.
22 July 2019
A large clinical trial in Africa and Asia has shown that a 7 day course of high dose primaquine, a drug used to treat P. vivax malaria, is well tolerated and just as effective as the current standard 14 day regimen, according to a study published this week in The Lancet. These findings have important implications for the treatment and elimination of vivax malaria in the Asia Pacific.